119 related articles for article (PubMed ID: 32599362)
1. Design, synthesis, bioevaluation of LFC- and PA-tethered anthraquinone analogues of mitoxantrone.
Xie XW; Liu ZP; Li X
Bioorg Chem; 2020 Aug; 101():104005. PubMed ID: 32599362
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of 3,5-substituted 1,2,4-oxadiazoles as catalytic inhibitors of human DNA topoisomerase IIα.
Loboda KB; Valjavec K; Štampar M; Wolber G; Žegura B; Filipič M; Dolenc MS; Perdih A
Bioorg Chem; 2020 Jun; 99():103828. PubMed ID: 32315896
[TBL] [Abstract][Full Text] [Related]
3. Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity.
Bist G; Park S; Song C; Thapa Magar TB; Shrestha A; Kwon Y; Lee ES
Eur J Med Chem; 2017 Jun; 133():69-84. PubMed ID: 28384547
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, biological evaluation, structure-activity relationship study, and mode of action of 2-phenol-4,6-dichlorophenyl-pyridines.
Shrestha A; Park S; Shin S; Man Kadayat T; Bist G; Katila P; Kwon Y; Lee ES
Bioorg Chem; 2018 Sep; 79():1-18. PubMed ID: 29715635
[TBL] [Abstract][Full Text] [Related]
5. Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase IIα.
Bergant K; Janežič M; Valjavec K; Sosič I; Pajk S; Štampar M; Žegura B; Gobec S; Filipič M; Perdih A
Eur J Med Chem; 2019 Aug; 175():330-348. PubMed ID: 31096154
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.
Kitdumrongthum S; Reabroi S; Suksen K; Tuchinda P; Munyoo B; Mahalapbutr P; Rungrotmongkol T; Ounjai P; Chairoungdua A
Biomed Pharmacother; 2020 Jul; 127():110149. PubMed ID: 32344256
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone, More than Just Another Topoisomerase II Poison.
Evison BJ; Sleebs BE; Watson KG; Phillips DR; Cutts SM
Med Res Rev; 2016 Mar; 36(2):248-99. PubMed ID: 26286294
[TBL] [Abstract][Full Text] [Related]
9. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
[TBL] [Abstract][Full Text] [Related]
10. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
[TBL] [Abstract][Full Text] [Related]
11. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines as selective topoisomerase IIα-targeting anticancer agents.
Magar TBT; Seo SH; Kadayat TM; Jo H; Shrestha A; Bist G; Katila P; Kwon Y; Lee ES
Bioorg Med Chem; 2018 May; 26(8):1909-1919. PubMed ID: 29510948
[TBL] [Abstract][Full Text] [Related]
13. Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase IIα catalytic inhibitor.
Kadayat TM; Park C; Jun KY; Thapa Magar TB; Bist G; Yoo HY; Kwon Y; Lee ES
Eur J Med Chem; 2015 Jan; 90():302-14. PubMed ID: 25437617
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel perimidine o-quinone derivatives as non-intercalative topoisomerase II catalytic inhibitors.
Zhou DC; Lu YT; Mai YW; Zhang C; Xia J; Yao PF; Wang HG; Huang SL; Huang ZS
Bioorg Chem; 2019 Oct; 91():103131. PubMed ID: 31377387
[TBL] [Abstract][Full Text] [Related]
15. Design and Synthesis of 3,4-diarylpyrrole Analogues as Potent Topoisomerase Inhibitors.
Chen W; Feng Z; He X; Zhao Q; Liang Q
Med Chem; 2018; 14(5):485-494. PubMed ID: 29485001
[TBL] [Abstract][Full Text] [Related]
16. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Lu Y; Yin W; Alam MS; Kadi AA; Jahng Y; Kwon Y; Rahman AFMM
Anticancer Agents Med Chem; 2020; 20(4):464-475. PubMed ID: 31763968
[TBL] [Abstract][Full Text] [Related]
18. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
[TBL] [Abstract][Full Text] [Related]
19. XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.
Ranganathan P; Kashyap T; Yu X; Meng X; Lai TH; McNeil B; Bhatnagar B; Shacham S; Kauffman M; Dorrance AM; Blum W; Sampath D; Landesman Y; Garzon R
Clin Cancer Res; 2016 Dec; 22(24):6142-6152. PubMed ID: 27358488
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y
Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
